ACAAI 2024 Advanced Practice Course

October 25, 2024

Advancing Allergy & Immunology Care

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.5 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Target Audience

  • All practicing allergists/immunologists
  • Fellows in allergy/immunology training programs
  • Primary care physicians who care for allergy patients
  • Allied health professionals in the field of allergy and immunology 

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Identify major advances in key areas of cutting edge research in immunologic mechanisms and allergic responses, including anaphylaxis and pathophysiology of the upper airways, lungs, eyes, skin and gastrointestinal tract
  • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency
  • Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases
  • Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases
  • Explain the impact of environmental exposures and external influences on patients with allergic disorders
  • Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health
  • Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes
  • Discuss processes, tools and technologies for the efficient allergy and immunology practice
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers


The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

 

Course summary
Available credit: 
  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 Attendance
  • 7.50 CBRN
Course opens: 
10/25/2024
Course expires: 
10/25/2024
Event starts: 
10/25/2024 - 8:00am CDT
Event ends: 
10/25/2024 - 4:30pm CDT
Add to calendar: 
Hynes Convention Center
Boston, MA
United States

All identified conflicts of interest have been resolved.

Education Staff/Committee/Reviewers have no relevant financial relationships to disclose, except as may be listed above.

 

 

Available Credit

  • 7.50 AMA PRA Category 1 Credit™
  • 7.50 Attendance
  • 7.50 CBRN
Please login or create an account to take this course.